Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1711 to 1725 of 7682 results

  1. Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

    In development [GID-TA10251] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Adrenal dysfunction

    Awaiting development [GID-QS10038] Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Pain management (young people and adults)

    Awaiting development [GID-QS10093] Expected publication date: TBC

    Quality standard
    Awaiting development

  4. Pancreatitis (including acute pancreatitis)

    Awaiting development [GID-QS10085] Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Thyroid disease

    Awaiting development [GID-QS10088] Expected publication date: TBC

    Quality standard
    Awaiting development

  6. Sleep disordered breathing

    Awaiting development [GID-QS10096] Expected publication date: TBC

    Quality standard
    Awaiting development

  7. Managing symptoms with an uncertain cause

    Awaiting development [GID-QS10103] Expected publication date: TBC

    Quality standard
    Awaiting development

  8. Secondary care management of malignant hypertension

    Awaiting development [GID-QS10107] Expected publication date: TBC

    Quality standard
    Awaiting development

  9. Prevention of dementia

    Awaiting development [GID-QS10109] Expected publication date: TBC

    Quality standard
    Awaiting development

  10. Gambling

    Awaiting development [GID-QS10099] Expected publication date: TBC

    Quality standard
    Awaiting development

  11. Vulnerable populations: strategies for tackling inequalities

    Awaiting development [GID-QS10124] Expected publication date: TBC

    Quality standard
    Awaiting development

  12. Gout

    Awaiting development [GID-QS10100] Expected publication date: TBC

    Quality standard
    Awaiting development

  13. Asunercept for treating glioblastoma [1301]

    In development [GID-TA10227] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]

    In development [GID-TA10225] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Glatiramer acetate depot for multiple sclerosis [TS ID 10620]

      Status ...

    Technology appraisal guidance
    Topic selection